About: Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report
Creator	De Martino, Maurizio Facchini, Ludovica Farina, Silvia Lucchesi, Maurizio Materassi, Marco Melosi, Francesca Roperto, Rosa Sardi, Iacopo Stival, Alessia Tintori, Veronica
Source	PMC
abstract	BACKGROUND: The incidence of gemcitabine-induced hemolytic uremic syndrome has already been described in adults. Several approaches have been employed in the treatment of gemcitabine-induced hemolytic uremic syndrome with different outcomes. One of the most promising agents is eculizumab, which is a monoclonal antibody directed against C5 complement protein. CASE PRESENTATION: We reported the case of a 3-year-old white boy with medulloblastoma who underwent high-dose chemotherapy and craniospinal irradiation. Afterwards he started maintenance chemotherapy with gemcitabine and oxaliplatin. After five courses he presented a progressive clinical worsening, which resulted in a systemic thrombotic microangiopathy. Initially he was treated with rituximab without clinical improvement. Therefore he started therapy with repeated cycles of eculizumab. After seven infusions he showed a gradual improvement and finally a complete remission of gemcitabine-induced hemolytic uremic syndrome. CONCLUSIONS: Eculizumab prevents serious complement-mediated vascular damage for chemotherapy-induced thrombotic microangiopathy in pediatric cases.
has issue date	2017-07-27(xsd:dateTime)
bibo:doi	10.1186/s13256-017-1373-5
bibo:pmid	28747219
has license	cc-by
sha1sum (hex)	de267b85447ec559ce0681d04fbd87422902a7a5
schema:url	https://doi.org/10.1186/s13256-017-1373-5
resource representing a document's title	Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report
has PubMed Central identifier	PMC5530476
has PubMed identifier	28747219
schema:publication	J Med Case Rep
resource representing a document's body	covid:de267b85447ec559ce0681d04fbd87422902a7a5#body_text
is schema:about of	named entity 'One' named entity 'ADULTS' covid:arg/de267b85447ec559ce0681d04fbd87422902a7a5 named entity 'directed' named entity 'protein' named entity 'respiratory distress' named entity 'pediatric patients' named entity 'adverse event' named entity 'eculizumab' named entity 'renal failure' named entity 'thiotepa' named entity 'thrombocytopenia' named entity 'eculizumab' named entity '21 days' named entity 'hemolytic anemia' named entity 'acute renal failure' named entity 'Intensive Care Unit' named entity 'overtreated' named entity 'MRI scan' named entity 'thrombotic microangiopathy' named entity 'gemcitabine' named entity 'ciprofloxacin' named entity 'high blood pressure' named entity 'lung' named entity 'thrombotic' named entity 'therapeutic drug' named entity 'hypertension' named entity 'Eculizumab' named entity 'irritability' named entity 'thrombotic microangiopathy' named entity 'Klebsiella' named entity 'apnea' named entity 'microangiopathic hemolysis' named entity 'heterogeneity' named entity 'medulla' named entity 'teicoplanin' named entity 'remission' named entity 'bronchospasm' named entity 'furosemide' named entity 'respiratory symptoms' named entity 'thrombospondin' named entity 'antibiotic therapy' named entity 'antihypertensive drugs' named entity 'creatinine' named entity 'CNS' named entity 'proteinuria' named entity 'immunosuppressive' named entity 'pneumocystosis' named entity 'thrombophilia' named entity 'headache' named entity 'transient response' named entity 'headache' named entity 'Creatinine' named entity '12 weeks' named entity 'maintenance chemotherapy' named entity 'CSF' named entity 'immunoglobulins' named entity 'medulloblastoma' named entity 'Mycoplasma pneumoniae' named entity 'eculizumab' named entity 'physical examination' named entity 'eculizumab' named entity 'meta-analysis' named entity 'plasmapheresis' named entity 'renal function' named entity 'eculizumab' named entity 'pediatric' named entity 'Blood cultures' named entity 'peripheral edema' named entity 'posterior fossa' named entity 'lesion' named entity 'cytology'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software